@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix chebi: .
@prefix go: .
@prefix Protein: .
@prefix hgnc: .
@prefix geneProductOf: .
@prefix hasAgent: .
@prefix do: .
@prefix occursIn: .
@prefix obo: .
@prefix species: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 hasAgent: sub:_2;
a go:0016301 .
sub:_2 geneProductOf: hgnc:392;
a Protein: .
sub:_3 occursIn: do:1107, obo:UBERON_0001043, species:9606;
rdf:object sub:_1;
rdf:predicate belv:decreases;
rdf:subject chebi:52289;
a rdf:Statement .
sub:assertion rdfs:label "a(CHEBI:wortmannin) -| kin(p(HGNC:AKT2))" .
}
sub:provenance {
beldoc: dce:description "Approximately 61,000 statements.";
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
dce:title "BEL Framework Large Corpus Document";
pav:authoredBy sub:_5;
pav:version "20131211" .
sub:_4 prov:value "The Akt2-specific antibody detected a marked electrophoretic mobility shift in TE-2, TE-8, and TE-10 cells in response to EGF stimulation, and there was no obvious mobility shift in TE-5, TE-9, and TE-12 cells (Fig. 9 A). The PI3K inhibitor wortmannin or LY294002 inhibited the Akt2 mobility shift in TE-2, TE-8, and TE-10 cells (Fig. 9 B),";
prov:wasQuotedFrom pubmed:10908564 .
sub:_5 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:10908564;
prov:wasDerivedFrom beldoc:, sub:_4 .
}
sub:pubinfo {
this: dcterms:created "2014-07-03T14:31:36.318+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}